Brief Report: Enhancement of Patient Recruitment in Rheumatoid Arthritis Clinical Trials Using a Multi‐Biomarker Disease Activity Score as an Inclusion Criterion

• Published in: Arthritis & rheumatology (Hoboken, N.J.) N.J.), 2015-11, Vol.67 (11), p.2855-2860
• Main Authors: van Vollenhoven, Ronald F., Bolce, Rebecca, Hambardzumyan, Karen, Saevarsdottir, Saedis, Forslind, Kristina, Petersson, Ingemar F., Sasso, Eric H., Hwang, C. C., Segurado, Oscar G., Geborek, Pierre
• Format: Article
• Language: English
• Subjects: Adult; Antirheumatic Agents - therapeutic use; Arthritis, Rheumatoid - diagnosis; Arthritis, Rheumatoid - drug therapy; Clinical Medicine; Clinical trials; Clinical Trials as Topic; Drug Therapy, Combination; Female; Humans; Klinisk medicin; Male; Medical and Health Sciences; Medicin och hälsovetenskap; Methotrexate - therapeutic use; Middle Aged; Patient Selection; Recruitment; Reumatologi och inflammation; Rheumatoid Arthritis; Rheumatology and Autoimmunity; Severity of Illness Index
• ISSN: 2326-5191; 2326-5205; 2326-5205
• DOI: 10.1002/art.39274

Objective Rheumatoid arthritis (RA) clinical trials often exclude patients who have low C‐reactive protein (CRP) levels, which slows enrollment into the trial. The purpose of this study was to determine whether high Multi‐Biomarker Disease Activity (MBDA) scores (>44) in RA patients with low CRP levels (≤10 mg/liter) could be used as a complement to CRP levels >10 mg/liter to enhance patient recruitment without affecting clinical trial outcomes. Methods We evaluated patients from the Swedish Pharmacotherapy (SWEFOT) trial, which did not include any selection criteria for CRP levels. Clinical outcomes were assessed after 3 months of methotrexate (MTX) monotherapy in MTX‐naive RA patients (n = 220) and after 3–10 months of add‐on therapy in patients who were incomplete responders to MTX alone (MTX‐IR) (n = 127). Radiographic outcomes were assessed at 1 year in all patients. Within each cohort, the outcomes were compared between patients with a CRP level of ≤10 mg/liter and an MBDA score of >44 at the start of the respective treatment interval versus those with a CRP level of >10 mg/liter. Results Patients with both a CRP level of ≤10 mg/liter and an MBDA score of >44 at baseline had clinical and radiographic outcomes that were comparable to those in patients with a CRP level of >10 mg/liter at baseline. This broadened definition of the inclusion criteria identified an additional 24% of patients in the MTX‐naive cohort and 47% in the MTX‐IR cohort. Conclusion Patient recruitment into RA clinical trials may be substantially enhanced, without any decrease in clinical and radiographic outcomes, by using as an inclusion criterion “a CRP level of >10 mg/liter and/or an MBDA score of >44.”